Affiliation:
1. The Third Affiliated Clinical Institute of Wenzhou Medical University
2. Second Affiliated Hospital & Yuying Children's Hospital of Wenzhou Medical University
Abstract
Abstract
Diabetic nephropathy (DN) is a prototypical chronic energy metabolism imbalance disease. The AMPK/Sirt1/PGC-1α signaling pathway plays a pivotal role in regulating energy metabolism throughout the body. Gut microbiota ferment indigestible carbohydrates to produce a variety of metabolites, particularly short-chain fatty acids (SCFAs), which exert positive effects on energy metabolism. However, the potential for SCFAs to ameliorate DN-associated renal injury via the AMPK/Sirt1/PGC-1α pathway remains a matter of debate. In this study, we investigated the effects of sodium butyrate (NaB), a SCFA, on energy metabolism in mice with spontaneous DN at two different doses. Body weight, blood glucose and lipid levels, urinary protein excretion, liver and kidney function, interleukin-6 (IL-6) levels, and the expressions of AMPK, phosphorylated AMPK (p-AMPK), mitofusin 2 (MFN2), optic atrophy 1 (OPA1), and glucagon-like peptide-1 receptor (GLP-1R) were monitored in mice. Additionally, butyrate levels, gut microbiota composition, and diversity in colonic stool were also assessed. Our findings demonstrate that exogenous NaB supplementation can improve hyperglycemia and albuminuria, reduce renal tissue inflammation, inhibit extracellular matrix accumulation and glomerular hypertrophy, and increase intestinal butyrate content while altering the gut microbiota composition in DN. Furthermore, NaB was found to upregulate the expressions of MFN2, OPA1, p-AMPK, and GLP-1R in DN renal tissue. These results suggest that NaB can improve the composition of gut microbiota in DN, activate the AMPK/Sirt1/PGC-1α signaling pathway, and enhance mitochondrial function to regulate energy metabolism throughout the body. Collectively, our findings indicate that NaB may be a novel therapeutic agent for the treatment of DN.
Publisher
Research Square Platform LLC
Reference31 articles.
1. Global aetiology and epidemiology of type 2 diabetes mellitus and its complications[J];Zheng Y;Nature Reviews Endocrinology,2018
2. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th edition[J];Saeedi P;Diabetes Research and Clinical Practice,2019
3. Crosstalk between endoplasmic reticulum stress and oxidative stress in the progression of diabetic nephropathy[J];Victor P;Cell Stress and Chaperones,2021
4. Diabetic gut microbiota dysbiosis as an inflammaging and immunosenescence condition that fosters progression of retinopathy and nephropathy[J]. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease;Fernandes R,2019
5. Samsu N. Diabetic Nephropathy: Challenges in Pathogenesis, Diagnosis, and Treatment[J]. Biomed Res Int, 2021, 2021: 1497449.